Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.
Castle Biosciences recently reported preliminary, unaudited fourth-quarter and full-year 2025 results, highlighting very ...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
Pacira BioSciences recently reported preliminary unaudited 2025 revenue of US$726.4 million, up from US$701.0 million in 2024 ...
Truist analyst Gregory Renza raised the firm’s price target on Ideaya Biosciences (IDYA) to $60 from $59 and keeps a Buy rating on the shares.
The next-gen, Unreal Engine 5-built Tomb Raider that developer Crystal Dynamics announced three years ago now has an official name and release window. Lara Croft’s new adventure for PC, PS5, and Xbox ...
Colossal Biosciences is pulling one final surprise out of its hat in 2025. Announced today, the company’s nonprofit arm—The Colossal Foundation—secured an additional $50 million in funding, doubling ...
One of many exciting reveals at last week's The Game Awards included the announcement of not one, but two Tomb Raider games currently in development at Crystal Dynamics. The first: a remake of 1996's ...
The Tomb Raider: Catalyst team has confirmed where the upcoming game sits in the series timeline. According to game director Will Kerslake, Catalyst - which will see the globe trotting Lara Croft ...
GameSpot may get a commission from retail offers. The Tomb Raider franchise is one of the most prolific and longest-running in all of gaming, and we got a tease of what's next for protagonist Lara ...
Along with a ton of exciting announcements from the 2025 Game Awards, Tomb Raider: Catalyst was just announced. That's right, folks, after waiting for around about seven years for a new Tomb Raider ...
Don't worry though, it's designed "for everyone" When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Before 2013's Tomb Raider rebooted Lara Croft's ...